MDGL רווח נקי למניה ב-12 החודשים האחרונים madrigalpharma.com

Madrigal Pharmaceuticals (MDGL) is expanding the production of therapies for metabolic liver pathologies in the US, leveraging the first approved drug in the niche. The company's 12-month profit per unit reflects asset dynamics, where the -5.97 mark indicates the yield level. Market capitalization is based on exclusive sales of Rezdiffra, creating a monopoly ecosystem for NASH treatment under FDA supervision.
פילוחים אנליטיים ודוחות נתונים של חברת Madrigal Corp (MDGL)

Annual net earnings per share aggregate the final financial result distributed across the total volume of issuance, allowing for an assessment of the real return on each ownership stake. By analyzing the 12-month rolling EPS, an investor can benchmark the efficiency of Madrigal Pharmaceuticals (MDGL) against its competitors, given that the production outsourcing model via SLA contracts minimizes capital expenditures, directly impacting final profitability.